{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3188, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "other", "function": "illustrate_case", "notes": "Includes longitudinal CT scan imagery and a line chart tracking tumor diameter and volume reduction.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/10", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-10", "loopMatches": [ { "to": 18, "from": 8, "name": "Jobs To Be Done", "slug": "53-jobs-to-be-done", "bestFor": "Product innovation, market entry, competitive positioning", "matchId": "0a2012e0-6a06-4e15-803c-e8ae832be1d6", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 1, "objective": "How can TRuC-T cell therapy address the needs of patients with solid tumors?", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "confidence": 0.7, "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying" } ], "arcBeatMatches": [ { "to": 18, "from": 8, "beatId": "fd7bc9b8-ed02-40c1-b1d1-66cb54ef449d", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "key_takeaways", "function": "analyze_data", "notes": "Waterfall plot shows individual patient responses; ORR, PFS, and OS metrics provided.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/11", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-11", "loopMatches": [ { "to": 18, "from": 8, "name": "Jobs To Be Done", "slug": "53-jobs-to-be-done", "bestFor": "Product innovation, market entry, competitive positioning", "matchId": "0a2012e0-6a06-4e15-803c-e8ae832be1d6", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 1, "objective": "How can TRuC-T cell therapy address the needs of patients with solid tumors?", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "confidence": 0.7, "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying" } ], "arcBeatMatches": [ { "to": 18, "from": 8, "beatId": "fd7bc9b8-ed02-40c1-b1d1-66cb54ef449d", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a central human anatomy diagram to map specific cancer types to their respective mesothelin expression rates.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/12", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-12", "loopMatches": [ { "to": 18, "from": 8, "name": "Jobs To Be Done", "slug": "53-jobs-to-be-done", "bestFor": "Product innovation, market entry, competitive positioning", "matchId": "0a2012e0-6a06-4e15-803c-e8ae832be1d6", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 1, "objective": "How can TRuC-T cell therapy address the needs of patients with solid tumors?", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "confidence": 0.7, "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying" } ], "arcBeatMatches": [ { "to": 18, "from": 8, "beatId": "fd7bc9b8-ed02-40c1-b1d1-66cb54ef449d", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 12, "from": 12, "beatId": "ec90fa2c-0c7b-4213-9966-0575ae439a11", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "The document discusses the market potential for TRuC-T cell therapy.", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a vertical process flow to link four strategic modifications to two distinct patient groups (Ovarian/Mesothelioma and NSCLC/Cholangiocarcinoma).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/13", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-13", "loopMatches": [ { "to": 18, "from": 8, "name": "Jobs To Be Done", "slug": "53-jobs-to-be-done", "bestFor": "Product innovation, market entry, competitive positioning", "matchId": "0a2012e0-6a06-4e15-803c-e8ae832be1d6", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 1, "objective": "How can TRuC-T cell therapy address the needs of patients with solid tumors?", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "confidence": 0.7, "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying" } ], "arcBeatMatches": [ { "to": 18, "from": 8, "beatId": "fd7bc9b8-ed02-40c1-b1d1-66cb54ef449d", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/14", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-14", "loopMatches": [ { "to": 18, "from": 8, "name": "Jobs To Be Done", "slug": "53-jobs-to-be-done", "bestFor": "Product innovation, market entry, competitive positioning", "matchId": "0a2012e0-6a06-4e15-803c-e8ae832be1d6", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 1, "objective": "How can TRuC-T cell therapy address the needs of patients with solid tumors?", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "confidence": 0.7, "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying" } ], "arcBeatMatches": [ { "to": 18, "from": 8, "beatId": "fd7bc9b8-ed02-40c1-b1d1-66cb54ef449d", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "other", "function": "present_framework", "notes": "The slide uses a process diagram to illustrate the dose escalation cohorts leading to the Recommended Phase 2 Dose (RP2D).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/15", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-15", "loopMatches": [ { "to": 18, "from": 8, "name": "Jobs To Be Done", "slug": "53-jobs-to-be-done", "bestFor": "Product innovation, market entry, competitive positioning", "matchId": "0a2012e0-6a06-4e15-803c-e8ae832be1d6", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 1, "objective": "How can TRuC-T cell therapy address the needs of patients with solid tumors?", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "confidence": 0.7, "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying" } ], "arcBeatMatches": [ { "to": 18, "from": 8, "beatId": "fd7bc9b8-ed02-40c1-b1d1-66cb54ef449d", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" }, { "to": 15, "from": 15, "beatId": "4ca3c30c-a6d7-4c34-8a47-6147b35a76fc", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document provides details on the Phase 1 trial in MSLN+ solid tumors.", "position": 4, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "appendix_data", "function": "analyze_data", "notes": "RP2D (Recommended Phase 2 Dose) is highlighted at DL 3.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/16", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-16", "loopMatches": [ { "to": 18, "from": 8, "name": "Jobs To Be Done", "slug": "53-jobs-to-be-done", "bestFor": "Product innovation, market entry, competitive positioning", "matchId": "0a2012e0-6a06-4e15-803c-e8ae832be1d6", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 1, "objective": "How can TRuC-T cell therapy address the needs of patients with solid tumors?", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "confidence": 0.7, "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying" } ], "arcBeatMatches": [ { "to": 18, "from": 8, "beatId": "fd7bc9b8-ed02-40c1-b1d1-66cb54ef449d", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "appendix_data", "function": "analyze_data", "notes": "The table categorizes adverse events into Hematologic, On Target/On Tumor, On Target/Off Tumor, and Other, with a specific highlight on the RP2D (Recommended Phase 2 Dose) column.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/17", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-17", "loopMatches": [ { "to": 18, "from": 8, "name": "Jobs To Be Done", "slug": "53-jobs-to-be-done", "bestFor": "Product innovation, market entry, competitive positioning", "matchId": "0a2012e0-6a06-4e15-803c-e8ae832be1d6", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 1, "objective": "How can TRuC-T cell therapy address the needs of patients with solid tumors?", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "confidence": 0.7, "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying" } ], "arcBeatMatches": [ { "to": 18, "from": 8, "beatId": "fd7bc9b8-ed02-40c1-b1d1-66cb54ef449d", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "appendix_data", "function": "analyze_data", "notes": "Waterfall plot is a standard clinical trial visualization for tumor response.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/18", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-18", "loopMatches": [ { "to": 18, "from": 8, "name": "Jobs To Be Done", "slug": "53-jobs-to-be-done", "bestFor": "Product innovation, market entry, competitive positioning", "matchId": "0a2012e0-6a06-4e15-803c-e8ae832be1d6", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 1, "objective": "How can TRuC-T cell therapy address the needs of patients with solid tumors?", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "confidence": 0.7, "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying" } ], "arcBeatMatches": [ { "to": 18, "from": 8, "beatId": "fd7bc9b8-ed02-40c1-b1d1-66cb54ef449d", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "appendix_data", "function": "analyze_data", "notes": "The chart uses a swimmer plot format to track longitudinal patient data including lymphodepletion status, response type, and survival.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/19", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-19", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The slide presents Kaplan-Meier curves for Progression-Free Survival and Overall Survival alongside a comparative table of historical study data.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/20", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-20", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "kpi_overview", "function": "analyze_data", "notes": "Includes waterfall plot of target lesion changes and Kaplan-Meier plots for PFS and OS.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/21", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-21", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "other", "function": "illustrate_case", "notes": "Includes longitudinal CT scan imagery and a line chart tracking tumor diameter and volume reduction over time.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/22", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-22", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide uses a scatter plot format with a shared legend for patient IDs and dose levels.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/23", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-23", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "appendix_data", "function": "analyze_data", "notes": "Data shows patient-specific longitudinal tracking of transgene copies/µg gDNA.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/24", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-24", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "appendix_data", "function": "analyze_data", "notes": "Patients with baseline levels of SMRP in normal range were excluded. Data cutoff: September 9, 2022.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/25", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-25", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/26", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-26", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The chart displays individual patient responses, with multiple patients achieving significant tumor regression.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/27", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "key_messages", "function": "present_solution", "notes": "The slide uses a numbered list format to categorize clinical trial improvements.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/28", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-28", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "appendix_methodology", "function": "present_framework", "notes": "Includes a futility analysis note for MPM arms and collaboration branding.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/29", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-29", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "comparison_table", "function": "analyze_data", "notes": "The chart shows the breakdown of patient eligibility by MSLN expression levels (50%, 2+/3+ vs 50%, 1+ vs Not eligible).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/30", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-30", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "key_takeaways", "function": "summarize", "notes": "The chart is a swimmer plot showing patient response over time, including redosing events and disease progression.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/31", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-31", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "before_after", "function": "diagnose_problem", "notes": "Uses multiparameter immunofluorescence to visualize tumor markers (PanCK), T cells (CD3), TAMs (CD68), and inhibitory ligands (CD155, PD-L1).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/32", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-32", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "roadmap", "function": "plan_implementation", "notes": "The chart uses horizontal bars to represent the development stage of each program.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/33", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-33", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5", "docSlug": "adb5c4514a6016378ffb63c7d4422971", "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides", "authorId": "tcr2-therapeutics", "authorName": "TCR2 Therapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "closing_ask", "function": "state_next_steps", "notes": "The slide features a large stylized '2' from the company logo as a background element.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/34", "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5", "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-34", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/sKrd1R_7JTzChvedVonQu7evsEFsYAzx2SyTGNvFl1A/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9mNmU2ZWUxOWJhOWQ3NzVjYTA2ZmIxN2Y4M2ViOGI3Zi9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/1", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/2KcYVD8em9FPiAcGQVnk-SRQ2bz1e-hUpqZncW2RTXQ/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9mNmU2ZWUxOWJhOWQ3NzVjYTA2ZmIxN2Y4M2ViOGI3Zi9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/_xro5XQOtZIJVPbSsoZ_yHahwgPuXg7RdRr85yuL59A/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9mNmU2ZWUxOWJhOWQ3NzVjYTA2ZmIxN2Y4M2ViOGI3Zi9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/gWw_IK3mnCkunEelNVOq2Oi8gxk4c21ZwjFs7IB5QsA/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9mNmU2ZWUxOWJhOWQ3NzVjYTA2ZmIxN2Y4M2ViOGI3Zi9wMDAxLnBuZw" }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 2, "slideType": "appendix_disclosure", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/2", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 3, "slideType": "appendix_data", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/3", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 4, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/4", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-4", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 5, "slideType": "problem_statement", "function": "frame_problem", "notes": "The slide uses a central hub-and-spoke diagram to show the mast cell as the central point of failure/intervention.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/5", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-5", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 6, "from": 5, "beatId": "d1a3d44c-6014-43c9-929f-a12d0af45eec", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The deck presents the problem statement on pages 5 and 6, highlighting the role of mast cells in allergy and inflammation.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 6, "slideType": "traction", "function": "show_traction", "notes": "The data highlights the mechanism of action of KIT inhibition (inactivation and depletion) supported by Phase 1b interim results.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/6", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-6", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 6, "from": 5, "beatId": "d1a3d44c-6014-43c9-929f-a12d0af45eec", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The deck presents the problem statement on pages 5 and 6, highlighting the role of mast cells in allergy and inflammation.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 7, "slideType": "product_demo", "function": "present_solution", "notes": "The slide presents a summary of preclinical efficacy and safety data alongside a table demonstrating high selectivity against other kinases.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/7", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-7", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 8, "from": 7, "beatId": "56e9f7b6-e6ea-4b9d-b393-88a0ff25d5c3", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The deck presents the solution on pages 7 and 8, introducing THB001 as a highly selective oral wild-type KIT inhibitor.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 8, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "The slide uses a staircase diagram to represent dose escalation and a crossover diagram for the food effect study.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/8", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-8", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 8, "from": 7, "beatId": "56e9f7b6-e6ea-4b9d-b393-88a0ff25d5c3", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The deck presents the solution on pages 7 and 8, introducing THB001 as a highly selective oral wild-type KIT inhibitor.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 9, "slideType": "appendix_data", "function": "analyze_data", "notes": "The chart displays multiple dose cohorts (200mg QD, 200mg BID, 400mg BID, 500mg QD FED) with error bars representing standard deviation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/9", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-9", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 10, "slideType": "appendix_data", "function": "analyze_data", "notes": "The table displays counts and percentages of subjects experiencing specific adverse events. 'MAD' stands for Multiple Ascending Dose.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/10", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-10", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 11, "slideType": "appendix_data", "function": "analyze_data", "notes": "The chart tracks neutrophil levels across multiple cohorts (placebo, 200mg QD, 200mg Q12H, 400mg Q12H, 500mg QD FED) from Day 1 to Day 70/EOS, with a vertical line marking the end of treatment at Day 14.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/11", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-11", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 12, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide includes a disclaimer that cross-study comparisons are unreliable due to differences in study design.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/12", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-12", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 13, "slideType": "appendix_data", "function": "analyze_data", "notes": "Includes two line charts: one normalized to baseline and one showing absolute values.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/13", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-13", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 14, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "The schematic illustrates a dose escalation study with three cohorts of 10 patients each, separated by safety review committee (SRC) checkpoints.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/14", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-14", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 15, "slideType": "traction", "function": "analyze_data", "notes": "The chart shows a pharmacokinetic (PK) profile comparing two formulations of THB001.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/15", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-15", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 16, "slideType": "other", "function": "establish_context", "notes": "The slide uses clinical data to justify a new indication for a drug candidate by highlighting the role of mast cells in asthma pathophysiology.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/16", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-16", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 17, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "The slide outlines a randomized, placebo-controlled trial structure with specific allergen challenge points.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/17", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-17", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 18, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a timeline diagram to show clinical phases and key events (trial initiation, regulatory submission, data readout) from 2H'22 to 2H'24.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/18", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-18", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 24, "from": 18, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "f318ece6-0617-4060-a8a8-460a299bc4cc", "evidence": "The deck presents multiple upcoming clinical catalysts and a clear development plan.", "position": 1, "objective": "Can THB001 achieve quick wins and make a big impact in the treatment of mast cell-mediated diseases?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 19, "slideType": "appendix", "function": "appendix", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/19", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-19", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 24, "from": 18, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "f318ece6-0617-4060-a8a8-460a299bc4cc", "evidence": "The deck presents multiple upcoming clinical catalysts and a clear development plan.", "position": 1, "objective": "Can THB001 achieve quick wins and make a big impact in the treatment of mast cell-mediated diseases?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 20, "slideType": "problem_statement", "function": "frame_problem", "notes": "Includes a patient quote and clinical imagery to emphasize the severity of the condition.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/20", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-20", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 24, "from": 18, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "f318ece6-0617-4060-a8a8-460a299bc4cc", "evidence": "The deck presents multiple upcoming clinical catalysts and a clear development plan.", "position": 1, "objective": "Can THB001 achieve quick wins and make a big impact in the treatment of mast cell-mediated diseases?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 21, "from": 20, "beatId": "3071eeb1-d844-41d8-a60d-a94623bcd39f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "The deck presents an overview of the market size on pages 20 and 21, discussing chronic urticaria and severe asthma.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 21, "slideType": "problem_statement", "function": "frame_problem", "notes": "Includes medical imagery of lungs and mast cells.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/21", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-21", "loopMatches": [ { "to": 21, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1637e937-fd9b-4682-939c-d684884ac925", "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.", "position": 0, "objective": "What is the cost of not treating mast cell-mediated diseases effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 24, "from": 18, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "f318ece6-0617-4060-a8a8-460a299bc4cc", "evidence": "The deck presents multiple upcoming clinical catalysts and a clear development plan.", "position": 1, "objective": "Can THB001 achieve quick wins and make a big impact in the treatment of mast cell-mediated diseases?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 21, "from": 20, "beatId": "3071eeb1-d844-41d8-a60d-a94623bcd39f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "The deck presents an overview of the market size on pages 20 and 21, discussing chronic urticaria and severe asthma.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 22, "slideType": "appendix_data", "function": "analyze_data", "notes": "DART stands for developmental and reproductive toxicology.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/22", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-22", "loopMatches": [ { "to": 24, "from": 18, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "f318ece6-0617-4060-a8a8-460a299bc4cc", "evidence": "The deck presents multiple upcoming clinical catalysts and a clear development plan.", "position": 1, "objective": "Can THB001 achieve quick wins and make a big impact in the treatment of mast cell-mediated diseases?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 23, "slideType": "appendix_data", "function": "analyze_data", "notes": "SAD = Single Ascending Dose; FE = Food Effect; PK = Pharmacokinetics; SAE = Serious Adverse Event; AE = Adverse Event; PBO = Placebo.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/23", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-23", "loopMatches": [ { "to": 24, "from": 18, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "f318ece6-0617-4060-a8a8-460a299bc4cc", "evidence": "The deck presents multiple upcoming clinical catalysts and a clear development plan.", "position": 1, "objective": "Can THB001 achieve quick wins and make a big impact in the treatment of mast cell-mediated diseases?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9947-75c9-ab6d-01a31b39af7e", "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f", "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides", "authorId": "third-harmonic-bio", "authorName": "Third Harmonic Bio", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7761332, "pageNumber": 24, "slideType": "appendix_data", "function": "analyze_data", "notes": "MAD = Multiple Ascending Dose study. Data shows transient changes in reticulocytes and hemoglobin levels during treatment.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/24", "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e", "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-24", "loopMatches": [ { "to": 24, "from": 18, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "f318ece6-0617-4060-a8a8-460a299bc4cc", "evidence": "The deck presents multiple upcoming clinical catalysts and a clear development plan.", "position": 1, "objective": "Can THB001 achieve quick wins and make a big impact in the treatment of mast cell-mediated diseases?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9a16-7158-8a43-7f4b71ce36ea", "docSlug": "444cc804081729af87feb225a86a4098", "documentTitle": "TurnOnGreen | Investor Presentation Deck | 23 slides", "authorId": "turnongreen", "authorName": "TurnOnGreen", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/HavdfPqRtL-osUxYxuh1eiGCMOzXezMLTw3lsJyHACI/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy80NDRjYzgwNDA4MTcyOWFmODdmZWIyMjVhODZhNDA5OC9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9a16-7158-8a43-7f4b71ce36ea/1", "deckHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea", "deckAnchorHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/1LwtjktKBznMcSn1fiZ73EQqO2f8EPEYm8K1g591evc/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy80NDRjYzgwNDA4MTcyOWFmODdmZWIyMjVhODZhNDA5OC9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/Y7AV88yneeag_YdBLCkIhiZs7R2PnEGWGfVnWw_TvVg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy80NDRjYzgwNDA4MTcyOWFmODdmZWIyMjVhODZhNDA5OC9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/nC4mxxo9ZlGIccBSrKAwpWVfwDLGkaj6JxbZeXtWTY4/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy80NDRjYzgwNDA4MTcyOWFmODdmZWIyMjVhODZhNDA5OC9wMDAxLnBuZw" }, { "docId": "019de073-9a16-7158-8a43-7f4b71ce36ea", "docSlug": "444cc804081729af87feb225a86a4098", "documentTitle": "TurnOnGreen | Investor Presentation Deck | 23 slides", "authorId": "turnongreen", "authorName": "TurnOnGreen", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 2, "slideType": "appendix_disclosure", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9a16-7158-8a43-7f4b71ce36ea/2", "deckHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea", "deckAnchorHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9a16-7158-8a43-7f4b71ce36ea", "docSlug": "444cc804081729af87feb225a86a4098", "documentTitle": "TurnOnGreen | Investor Presentation Deck | 23 slides", "authorId": "turnongreen", "authorName": "TurnOnGreen", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 3, "slideType": "context", "function": "establish_context", "notes": "The slide uses a timeline to show the evolution from Digital Power Corporation (1969) to the current public entity.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9a16-7158-8a43-7f4b71ce36ea/3", "deckHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea", "deckAnchorHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9a16-7158-8a43-7f4b71ce36ea", "docSlug": "444cc804081729af87feb225a86a4098", "documentTitle": "TurnOnGreen | Investor Presentation Deck | 23 slides", "authorId": "turnongreen", "authorName": "TurnOnGreen", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 4, "slideType": "team_bio", "function": "other", "notes": "The slide combines team bios with a mission statement.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9a16-7158-8a43-7f4b71ce36ea/4", "deckHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea", "deckAnchorHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 4, "beatId": "a237a2f3-9829-4a75-8959-de521b3b9f25", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "The deck presents the executive staff on page 4.", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9a16-7158-8a43-7f4b71ce36ea", "docSlug": "444cc804081729af87feb225a86a4098", "documentTitle": "TurnOnGreen | Investor Presentation Deck | 23 slides", "authorId": "turnongreen", "authorName": "TurnOnGreen", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 5, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9a16-7158-8a43-7f4b71ce36ea/5", "deckHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea", "deckAnchorHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea#slide-5", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9a16-7158-8a43-7f4b71ce36ea", "docSlug": "444cc804081729af87feb225a86a4098", "documentTitle": "TurnOnGreen | Investor Presentation Deck | 23 slides", "authorId": "turnongreen", "authorName": "TurnOnGreen", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 6, "slideType": "customer_logos", "function": "show_traction", "notes": "The slide highlights 50+ years of expertise and lists a diverse range of clients across defense, aerospace, and commercial sectors.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9a16-7158-8a43-7f4b71ce36ea/6", "deckHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea", "deckAnchorHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea#slide-6", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9a16-7158-8a43-7f4b71ce36ea", "docSlug": "444cc804081729af87feb225a86a4098", "documentTitle": "TurnOnGreen | Investor Presentation Deck | 23 slides", "authorId": "turnongreen", "authorName": "TurnOnGreen", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 7, "slideType": "market_sizing", "function": "analyze_data", "notes": "Data source: Kelley Blue Book 2022.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9a16-7158-8a43-7f4b71ce36ea/7", "deckHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea", "deckAnchorHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea#slide-7", "loopMatches": [], "arcBeatMatches": [ { "to": 7, "from": 7, "beatId": "b1687f7b-95d7-4eca-a9d4-d6f3060ed7bb", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "The deck presents market sizing information on page 7.", "position": 0, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9a16-7158-8a43-7f4b71ce36ea", "docSlug": "444cc804081729af87feb225a86a4098", "documentTitle": "TurnOnGreen | Investor Presentation Deck | 23 slides", "authorId": "turnongreen", "authorName": "TurnOnGreen", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 8, "slideType": "why_now", "function": "argue_timing", "notes": "The chart uses a combination of bar (quarterly) and line (cumulative) data to demonstrate market acceleration.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9a16-7158-8a43-7f4b71ce36ea/8", "deckHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea", "deckAnchorHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea#slide-8", "loopMatches": [ { "to": 9, "from": 8, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "f1425560-25b5-45bc-8438-29e6e4502b1a", "evidence": "The deck presents the 'why now' argument on pages 8-9.", "position": 0, "objective": "Explain why now is the right time for TurnOnGreen's solution", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.7, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [ { "to": 8, "from": 8, "beatId": "f5f3eeac-e60f-49f9-9a2d-d6739c867f1e", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The deck presents the problem statement on page 8.", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9a16-7158-8a43-7f4b71ce36ea", "docSlug": "444cc804081729af87feb225a86a4098", "documentTitle": "TurnOnGreen | Investor Presentation Deck | 23 slides", "authorId": "turnongreen", "authorName": "TurnOnGreen", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 9, "slideType": "context", "function": "establish_context", "notes": "Slide highlights California as a leader in EV adoption and policy, providing quantitative market data and state-level goals.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9a16-7158-8a43-7f4b71ce36ea/9", "deckHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea", "deckAnchorHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea#slide-9", "loopMatches": [ { "to": 9, "from": 8, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "f1425560-25b5-45bc-8438-29e6e4502b1a", "evidence": "The deck presents the 'why now' argument on pages 8-9.", "position": 0, "objective": "Explain why now is the right time for TurnOnGreen's solution", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.7, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9a16-7158-8a43-7f4b71ce36ea", "docSlug": "444cc804081729af87feb225a86a4098", "documentTitle": "TurnOnGreen | Investor Presentation Deck | 23 slides", "authorId": "turnongreen", "authorName": "TurnOnGreen", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 10, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a grid layout to map product categories against specific offerings.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9a16-7158-8a43-7f4b71ce36ea/10", "deckHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea", "deckAnchorHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea#slide-10", "loopMatches": [ { "to": 20, "from": 10, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "1990d216-9c78-4875-be2b-ad00e5be864a", "evidence": "The deck presents the solution overview and details on pages 10-20.", "position": 1, "objective": "Present the solution and its potential impact", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 10, "beatId": "0dd6b4fb-022d-47ab-9fc0-b57757b31610", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The deck presents the solution overview and details on pages 10-20.", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9a16-7158-8a43-7f4b71ce36ea", "docSlug": "444cc804081729af87feb225a86a4098", "documentTitle": "TurnOnGreen | Investor Presentation Deck | 23 slides", "authorId": "turnongreen", "authorName": "TurnOnGreen", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 11, "slideType": "segmentation", "function": "decompose_segments", "notes": "Uses asterisks to denote current vs future goals.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-9a16-7158-8a43-7f4b71ce36ea/11", "deckHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea", "deckAnchorHref": "/decks/019de073-9a16-7158-8a43-7f4b71ce36ea#slide-11", "loopMatches": [ { "to": 20, "from": 10, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "1990d216-9c78-4875-be2b-ad00e5be864a", "evidence": "The deck presents the solution overview and details on pages 10-20.", "position": 1, "objective": "Present the solution and its potential impact", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 10, "beatId": "0dd6b4fb-022d-47ab-9fc0-b57757b31610", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The deck presents the solution overview and details on pages 10-20.", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }